Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of ...

Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...